Humacyte
HUMA
70 hedge funds and large institutions have $74M invested in Humacyte in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 15 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
33% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $932K
15% more funds holding
Funds holding: 61 → 70 (+9)
7% more capital invested
Capital invested by funds: $69M → $74M (+$4.98M)
0.94% more ownership
Funds ownership: 9.25% → 10.18% (+0.94%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.3M |
| 2 |
PGP
Prescott General Partners
Boca Raton,
Florida
|
+$3.17M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.73M |
| 4 |
Millennium Management
New York
|
+$1.65M |
| 5 |
BlackRock
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$6.53M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.9M |
| 3 |
DCP
Diameter Capital Partners
New York
|
-$2.18M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.75M |
| 5 |
LPL Financial
San Diego,
California
|
-$1.73M |
HUMA Hedge Fund Activity: Q1 2022 in Review
70 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2022, worth a combined $74M — up 7.2% from $69M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new HUMA positions and 15 closed out — a net gain of 10 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $7.3M. The largest seller was UBS O'Connor, exiting entirely with an estimated $6.53M sold.
- 70 institutional investors held Humacyte (HUMA) as of Q1 2022, up from 61 in Q4 2021.
- Funds reported $74M of Humacyte stock for Q1 2022, up 7.2% quarter-over-quarter.
- 25 funds opened new Humacyte positions in Q1 2022 and 15 closed out, a net change of +10 holders.
- The largest Humacyte buyer in Q1 2022 was Vanguard Group, an estimated $7.3M added.
- The largest Humacyte seller in Q1 2022 was UBS O'Connor, an estimated $6.53M sold.
Based on aggregated 13F filings for Q1 2022.